1Coukll AJ,Markham A.Pamidronate:a review of its use inthe management of-osteolytic bone metastases Tumour-induced hypercalcaemia and Paget’’s disease of bone. DrugsAaing . 1998
7Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res, 1995, 10:1478-1487.
8Rogers MJ, Chilton KM, Coxon FP, et al. Bisphosphonates induce apoptosis in mouse maerophage-like ceils in vitro by a nitric oxideindependent mechanism. J Bone Miner Res, 1996, 11: 1482-1491.
9Rosen LS, Cordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disadium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 2003, 98 : 1735-1744.
10Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronie acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase Ⅲ, double-blind, randomized triM. J Clin Oncol, 2003, 21:3150-3157.
3Croucher P,Jagdev S,Coleman R. The anti-tumor potential of zoledronic acid[J]. Breast, 2003,12 Suppl 2 : S30-36.
4Rosen LS, Gordon D,Tchekmedyian NS, et al. Long-term effica- cy and safety of zoledronic acid in the treatment of skeletal meta- stases in patients with nonsmall cell lung carcinoma and other solid tumors : a randomized, Phase III, double-blind, placeboco- ntrolled trial[J].Cancer,2004,100(12) :2613-2621.
